Not FDA approved and sold as a research chemical. This page is educational information only. It is not medical advice and not a recommendation to use anything.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Pancragen

Not FDA approved

Short synthetic bioregulator peptide

Evidence score

14/ 100

Thin evidence

Very thin human evidence

Regulatory standing. Sold as a research chemical, not approved
Animal / preclinical only. Evidence is largely animal or in-vitro
No registered human trials. Nothing registered on ClinicalTrials.gov
No sources. Nothing cited to verify

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Pancragen is a short synthetic peptide from the Khavinson group of so-called bioregulator peptides developed in Russia, generally described as a tetrapeptide (often listed as Lys-Glu-Asp-Trp) modeled on pancreatic tissue extracts. It is proposed to influence gene expression and cell differentiation in pancreatic tissue, but this mechanism is not well established.

What the evidence shows

Automatic summaryAnimal / preclinical

The published literature is small, about seven papers, and consists mainly of cell culture and animal studies from a limited group of researchers. There are no registered human trials, so any effect on pancreatic function or blood sugar in people is unproven.

This name is shared with unrelated compounds in public databases, so trial and paper counts are not shown here, and the evidence score counts no registered trials. Treat this profile as a starting point only.

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.